| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8017105 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
May, 2015
(8 years ago) | |
| US7060250 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
May, 2015
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7011815 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
Feb, 2015
(9 years ago) | |
| US8394356 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
Feb, 2015
(9 years ago) | |
| US7229606 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
May, 2015
(8 years ago) | |
| US6676929 | LANTHEUS MEDCL | Diagnostic imaging contrast agents with extended blood retention |
May, 2020
(3 years ago) | |
Ablavar is owned by Lantheus Medcl.
Ablavar contains Gadofosveset Trisodium.
Ablavar has a total of 6 drug patents out of which 6 drug patents have expired.
Expired drug patents of Ablavar are:
- US7011815
- US8394356
- US7229606
- US6676929
- US8017105
- US7060250
Ablavar was authorised for market use on 22 December, 2008.
Ablavar is available in solution;intravenous dosage forms.
Ablavar can be used as method of mr imaging of a mammal.
Drug patent challenges can be filed against Ablavar from 22 December, 2012.
The generics of Ablavar are possible to be released after 04 May, 2020.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Dec 22, 2013 |
Drugs and Companies using GADOFOSVESET TRISODIUM ingredient
NCE-1 date: 22 December, 2012
Market Authorisation Date: 22 December, 2008
Treatment: Method of mr imaging of a mammal
Dosage: SOLUTION;INTRAVENOUS
ABLAVAR family patents
